MiR-133 is Involved in Estrogen Deficiency-Induced Osteoporosis Through Modulating Osteogenic Differentiation of Mesenchymal Stem Cells

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 May 28

PMID 26013661

Citations 28

Authors

Hao Lv

Yujie Sun

Yuchen Zhang

Affiliations

Soon will be listed here.

Abstract

Background: MiR-133 expression is dysregulated in postmenopausal osteoporosis. However, its role in postmenopausal osteoporosis is still not well understood. In the current study, we explore how estrogen deficiency affects miR-133 expression and how miR-133 is involved in osteogenic differentiation of mesenchymal stem cells (MSCs).

Material And Methods: qRT-PCR analysis was performed to assess miR-133 expression in MSCs isolated from bone marrow of an ovariectomized (OVX) animal model and postmenopausal osteoporosis patients (PMOP) and their corresponding controls. The binding between miR-133 and predicted target SLC39A1 was verified using dual luciferase assay and Western blot analysis. The effect of miR-133 and SLC39A1 on osteogenic differentiation of MSCs was assessed through measuring alkaline phosphatase (ALP), mineralization nodules, and osteoblast-specific genes Runx2 and Osterix expression.

Results: miR-133 expression is significantly enhanced as a result of estrogen deficiency. Its overexpression is negatively correlated to osteogenic differentiation of hMSCs. SLC39A1 showed an inverse expression trend to miR-133 during the differentiation. miR-133 can directly target 3'UTR of SLC39A1 and thereby modulate its expression in hMSCs. The miR-133-SLC39A1 axis might play an important role in osteogenic differentiation of hMSCs. SLC39A1 can promote ALP activity and formation of mineralization nodules. In addition, SLC39A1 expression level is also positively correlated with RUNX2 and Osterix.

Conclusions: Estrogen deficiency is associated with miR-133 overexpression. MiR-133 can induce postmenopausal osteoporosis by weakening osteogenic differentiation of hMSCs, at least partly through repressing SLC39A1 expression.

Citing Articles

miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.

Tavakoli Pirzaman A, Ebrahimi P, Hasanpour A, Shakeri M, Babajani B, Pourali Ganji Z Technol Cancer Res Treat. 2023; 22:15330338231202391.

PMID: 37728167 PMC: 10515583. DOI: 10.1177/15330338231202391.

Common miRNAs of Osteoporosis and Fibromyalgia: A Review.

Philippe S, Delay M, Macian N, Morel V, Pickering M Int J Mol Sci. 2023; 24(17).

PMID: 37686318 PMC: 10488272. DOI: 10.3390/ijms241713513.

Gender-Specific Differences in Human Vertebral Bone Marrow Clot.

Salamanna F, Contartese D, Borsari V, Pagani S, Sartori M, Tschon M Int J Mol Sci. 2023; 24(14).

PMID: 37511617 PMC: 10380734. DOI: 10.3390/ijms241411856.

Transcriptomic and Functional Evidence That miRNA193a-3p Inhibits Lymphatic Endothelial Cell (LEC) and LEC + MCF-7 Spheroid Growth Directly and by Altering MCF-7 Secretome.

Azzarito G, Henry M, Rotshteyn T, Leeners B, Dubey R Cells. 2023; 12(3).

PMID: 36766731 PMC: 9913637. DOI: 10.3390/cells12030389.

Micro-RNA193a-3p Inhibits Breast Cancer Cell Driven Growth of Vascular Endothelial Cells by Altering Secretome and Inhibiting Mitogenesis: Transcriptomic and Functional Evidence.

Azzarito G, Kurmann L, Leeners B, Dubey R Cells. 2022; 11(19).

PMID: 36230929 PMC: 9562882. DOI: 10.3390/cells11192967.

References

Qiu W, Kassem M . miR-141-3p inhibits human stromal (mesenchymal) stem cell proliferation and differentiation. Biochim Biophys Acta. 2014; 1843(9):2114-21. DOI: 10.1016/j.bbamcr.2014.06.004. View

Liao L, Yang X, Su X, Hu C, Zhu X, Yang N . Redundant miR-3077-5p and miR-705 mediate the shift of mesenchymal stem cell lineage commitment to adipocyte in osteoporosis bone marrow. Cell Death Dis. 2013; 4:e600. PMC: 3641352. DOI: 10.1038/cddis.2013.130. View

Tang P, Xiong Q, Ge W, Zhang L . The role of microRNAs in osteoclasts and osteoporosis. RNA Biol. 2015; 11(11):1355-63. PMC: 4615571. DOI: 10.1080/15476286.2014.996462. View

Liu X, Cai F, Liu L, Zhang Y, Yang A . MicroRNA-210 is involved in the regulation of postmenopausal osteoporosis through promotion of VEGF expression and osteoblast differentiation. Biol Chem. 2014; 396(4):339-47. DOI: 10.1515/hsz-2014-0268. View

Gaither L, Eide D . Functional expression of the human hZIP2 zinc transporter. J Biol Chem. 2000; 275(8):5560-4. DOI: 10.1074/jbc.275.8.5560. View

Eberle J, Schmidmayer S, Erben R, Stangassinger M, Roth H . Skeletal effects of zinc deficiency in growing rats. J Trace Elem Med Biol. 1999; 13(1-2):21-6. DOI: 10.1016/S0946-672X(99)80019-4. View

Tang Z, Sahu S, Khadeer M, Bai G, Franklin R, Gupta A . Overexpression of the ZIP1 zinc transporter induces an osteogenic phenotype in mesenchymal stem cells. Bone. 2005; 38(2):181-98. DOI: 10.1016/j.bone.2005.08.010. View

Epstein S . Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther. 2006; 28(2):151-73. DOI: 10.1016/j.clinthera.2006.02.007. View

Khosla S, Melton 3rd L, Riggs B . The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J Bone Miner Res. 2010; 26(3):441-51. PMC: 3179298. DOI: 10.1002/jbmr.262. View

10.

Eskildsen T, Taipaleenmaki H, Stenvang J, Abdallah B, Ditzel N, Nossent A . MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. Proc Natl Acad Sci U S A. 2011; 108(15):6139-44. PMC: 3076836. DOI: 10.1073/pnas.1016758108. View

11.

Zhao J, Gao Z, Mei H, Li Y, Wang Y . Differentiation of human mesenchymal stem cells: the potential mechanism for estrogen-induced preferential osteoblast versus adipocyte differentiation. Am J Med Sci. 2011; 341(6):460-8. DOI: 10.1097/MAJ.0b013e31820865d5. View

12.

Guan M, Yao W, Liu R, Lam K, Nolta J, Jia J . Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012; 18(3):456-62. PMC: 3755884. DOI: 10.1038/nm.2665. View

13.

Wang Y, Li L, Moore B, Peng X, Fang X, Lappe J . MiR-133a in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis. PLoS One. 2012; 7(4):e34641. PMC: 3323546. DOI: 10.1371/journal.pone.0034641. View

14.

Heiss C, Govindarajan P, Schlewitz G, Hemdan N, Schliefke N, Alt V . Induction of osteoporosis with its influence on osteoporotic determinants and their interrelationships in rats by DEXA. Med Sci Monit. 2012; 18(6):BR199-207. PMC: 3560729. DOI: 10.12659/msm.882895. View

15.

Zhang J, Fu W, He M, Xie W, Lv Q, Wan G . MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol. 2011; 8(5):829-38. DOI: 10.4161/rna.8.5.16043. View

16.

Yang N, Wang G, Hu C, Shi Y, Liao L, Shi S . Tumor necrosis factor α suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis. J Bone Miner Res. 2012; 28(3):559-73. DOI: 10.1002/jbmr.1798. View

17.

Yao W, Guan M, Jia J, Dai W, Lay Y, Amugongo S . Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells. 2013; 31(9):2003-14. PMC: 3795809. DOI: 10.1002/stem.1461. View

18.

Li H, Wang Z, Fu Q, Zhang J . Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients. Biomarkers. 2014; 19(7):553-6. DOI: 10.3109/1354750X.2014.935957. View